In chronic myeloid leukemia (CML), Nrf2 appears to promote drug resistance and reduce apoptotic susceptibility in K-562 cells, a human erythroleukemia cell line frequently used in redox and cancer research [35]. The gene discussed is NFE2L2; the disease is cancer.